Active Ingredient History
Trospium is an antispasmodic, antimuscarinic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Receptor assays showed that trospium has negligible affinity for nicotinic receptors as compared to muscarinic receptors at concentrations obtained from therapeutic doses. Trospium antagonizes the effect of acetylcholine on muscarinic receptors in cholinergically innervated organs. Its parasympatholytic action reduces the tonus of smooth muscle in the bladder. Trospium is marketed under the brand name Sancturain the US, Tropez OD in India,Trosec in Canada, Regurin and Flotros in the United Kingdom and Spasmex in Germany, Russia, Turkey, Argentina, Chile and Israel. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Accidental Falls (Early Phase 1)
Aged (Phase 4)
Cognition (Phase 4)
Drug Interactions (Phase 1)
Healthy Volunteers (Phase 1)
Mental Competency (Phase 4)
Obesity (Phase 4)
Pharmacokinetics (Phase 4)
Pulmonary Disease, Chronic Obstructive (Phase 2)
Schizophrenia (Phase 3)
Spinal Cord Injuries (Phase 4)
Urinary Bladder (Phase 4)
Urinary Bladder, Overactive (Phase 4)
Urinary Incontinence (Phase 4)
Urinary Incontinence, Urge (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
